Trial Profile
A Phase II Study of EL625 [Cenersen] in Patients in Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cenersen (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 21 Aug 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 31 Mar 2010 Actual patient number (20) added as reported by ClinicalTrials.gov.
- 31 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.